BeiGene's TEVIMBRA Gains Ground: New Approval Expands PD-1...

bir ses eklendi Health

2025-05-09 06:34:33

BeiGene's TEVIMBRA Gains Ground: New Approval Expands PD-1 Drug Portfolio

In a notable advancement for the immuno-oncology sector, BeiGene has secured an additional indication for its flagship immunotherapy TEVIMBRA (tislelizumab). This regulatory win strengthens the drug's competitive position in the increasingly crowded PD-1 drug marketplace, where established players like Merck's Keytruda have long dominated treatment protocols. Expanding Clinical...

0 Yorumlar 0 hisse senetleri 89 Views 0 önizleme